Learning Objectives
Upon completion of this activity, participants should be able to:
- Cite patient and drug factors that should be considered when planning first-line antiretroviral therapy
- Explain the preferred choices for first-line therapy as denoted by US treatment guidelines
- Discuss the data supporting the use of efavirenz as a first-line option with 2 NRTIs, including considerations regarding the choice between NNRTI-based and PI-based initial therapy
- Describe the advantages and disadvantages of the various boosted PI regimens recommended by the US treatment guidelines
- Recount factors influencing the choice between tenofovir/emtricitabine and abacavir/lamivudine in first-line regimens
Topics covered include:
- Introduction
- Individualizing Treatment Selection
- Treatment Guidelines: Preferred/Recommended Options
- Weighing NNRTI vs PI Options
- Weighing First-line Boosted PI Options
- Weighing NRTI Options
- Weighing Future Options
- Summary
Abstract